Evidence map›Paper›PMID 35454861›Full record

ArticleCancers2022

CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis.

Christoph Wohlmuth, Vladimir Djedovic, Susanne K Kjaer, Allan Jensen, Rosalind Glasspool, Patricia Roxburgh, Anna DeFazio, Sharon E Johnatty, Penelope M Webb, Francesmary Modugno and 19 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Comparison of [Abdominal radiology (New York) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 17 institutions in 9 countries.

Christoph WohlmuthDivision of Gynecologic Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON M5G 2M9, Canada.
Vladimir DjedovicDivision of Gynecologic Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON M5G 2M9, Canada.
Susanne K KjaerDepartment of Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-8347-1398
Allan JensenDepartment of Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark.
Rosalind GlasspoolBeatson West of Scotland Cancer Centre, University of Glasgow, Glasgow G12 0YN, UK.
Patricia RoxburghBeatson West of Scotland Cancer Centre, University of Glasgow, Glasgow G12 0YN, UK.
Anna DeFazioCentre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.ORCID 0000-0003-0057-4744
Sharon E JohnattyDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
Penelope M WebbPopulation Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.ORCID 0000-0003-0733-5930
Francesmary ModugnoWomen's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, PA 15213, USA.
Diether LambrechtsLaboratory for Translational Genetics, Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.
Joellen M SchildkrautDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
Andrew BerchuckDepartment of Gynecologic Oncology, Duke University Hospital, Durham, NC 27710, USA.
Liv Cecilie Vestrheim ThomsenDepartment of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway.ORCID 0000-0002-6787-8518
Line BjorgeDepartment of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway.ORCID 0000-0002-0240-2770
Estrid HøgdallDepartment of Pathology, Herlev Hospital, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID 0000-0003-4689-5658
Claus K HøgdallDepartment of Gynaecology, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-5959-8874
Ellen L GoodeDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
Stacey J WinhamDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
Keitaro MatsuoDivision of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan.ORCID 0000-0003-1761-6314
Beth Y KarlanDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-9451-2933
Jenny LesterDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA.
Marc T GoodmanCancer Prevention and Control Program, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Pamela J ThompsonSamuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Tanja PejovicDepartment of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR 97239, USA.
Marjorie J RigganDepartment of Gynecologic Oncology, Duke University Hospital, Durham, NC 27710, USA.
Katherine LajkoszBiostatistics, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2C1, Canada.
Alicia ToneDivision of Gynecologic Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON M5G 2M9, Canada.ORCID 0000-0001-9715-4273
Taymaa MayDivision of Gynecologic Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON M5G 2M9, Canada.
University Health Network · CAUniversity of Copenhagen · DKBeatson West of Scotland Cancer Centre · GBCedars-Sinai Medical Center · USDuke University Hospital · USHaukeland University Hospital · NOMayo Clinic in Florida · USQIMR Berghofer Medical Research Institute · AUUniversity of California, Los Angeles · USAichi Cancer Center · JPDanish Cancer Society · DKEmory University · USOregon Health & Science University · USThe University of Sydney · AUUniversity of Pittsburgh · USUniversity of Toronto · CAVIB-KU Leuven Center for Cancer Biology · BE

Funding

Relating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and RiskR01CA248288 · NCI · MAYO CLINIC ROCHESTER · PI Stacey J Winham · 2021 to 2026
$4.8M
NCI NIH HHS R01 CA248288Ovarian Cancer Research Fund PPD/RPCI.07
6 · The paper itself

Abstract

objectiveStudies on low-grade serous ovarian cancer (LGSC) are limited by a low number of cases. The aim of this study was to define the prognostic significance of age, stage, and CA-125 levels on survival in a multi-institutional cohort of women with pathologically confirmed LGSC.

methodsWomen with LGSC were identified from the collaborative Ovarian Cancer Association Consortium (OCAC). Cases of newly diagnosed primary LGSC were included if peri-operative CA-125 levels were available. Age at diagnosis, FIGO stage, pre- and post-treatment CA-125 levels, residual disease, adjuvant chemotherapy, disease recurrence, and vital status were collected by the participating institutions. Progression-free (PFS) and overall survival (OS) were calculated. Multivariable (MVA) Cox proportional hazard models were used and hazard ratios (HR) calculated.

resultsA total of 176 women with LGSC were included in this study; 82% had stage III/IV disease. The median PFS was 2.3 years and the median OS was 6.4 years. Age at diagnosis was not significantly associated with worse PFS (

conclusionAdvanced LGSC was associated with poor long-term prognosis. FIGO stage and abnormal post-treatment CA-125 level are key prognostic factors inversely associated with PFS and OS. HIGHLIGHTS: 1. Through a multi-center collaborative effort, data from 176 women with low-grade serous ovarian cancer were analyzed. 2. Although low-grade serous ovarian cancer is often considered indolent, the progression-free and overall survival are poor. 3. Elevated post-treatment CA-125 levels are independently associated with poor survival.

Indexed as

CA-125low-grade serous cancerovarian cancersurvival

Identifiers

PMID35454861
PMCPMC9024456
OpenAlexW4223975396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.